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The immune system plays a central role in cancer development, showing both anti-tumor
and pro-tumor activities depending on the immune cell subsets and the disease context.
While CD8T cells are associated with a favorable outcome in most cancers, only T
helper type 1 (Th1) CD4T cells play a protective role, in contrast to Th2 CD4T cells.
Double positive (DP) CD4+CD8+ T cells remain understudied, although they were already
described in human cancers, with conflicting data regarding their role. Here, we quantified
and phenotypically/functionally characterized DP T cells in blood from urological cancer
patients. We analyzed blood leukocytes of 24 healthy donors (HD) and 114 patients
with urological cancers, including bladder (n = 54), prostate (n = 31), and kidney (n
= 29) cancer patients using 10-color flow cytometry. As compared to HD, levels of
circulating DP T cells were elevated in all urological cancer patients, which could be
attributed to increased frequencies of both CD4highCD8low and CD4+CD8high DP T-cell
subsets. Of note, most CD4highCD8low DP T cells show a CD8αα phenotype, whereas
CD4+CD8high cells express both CD8α and CD8β subunits. Functional properties were
investigated using ex-vivo generated DP T-cell clones. DP T cells from patients were
skewed toward an effector memory phenotype, along with enhanced Th2 cytokine
production. Interestingly, both CD8αα and CD8αβ DP T cells were able to trigger
Th2 polarization of naïve CD4T cells, while restraining Th1 induction. Thus, these
data highlight a previously unrecognized immunoregulatory mechanism involving DP
CD4+CD8+ T cells in urological cancers.
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INTRODUCTION
The crucial role of anti-tumor immune responses in cancer patients has been intensively
studied during the last two decades, leading to unprecedented opportunities to effectively
treat several malignancies (1–4). However, mechanisms hindering efficient immune responses
to human tumors still need to come under closer scrutiny, and the complex interplay
between various immune cell-subsets requires being well-deciphered to improve or design
novel immunotherapeutic strategies. CD8+ T cells and type-1 helper CD4+ T cells
(Th1) are thought to play a major role in effective anti-tumor responses, and thus
associate to good prognosis in most human cancers (4, 5). In contrast, Th2 CD4+
T cells—which are involved in humoral immunity by providing B-cell help—are more
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often associated to poor prognosis (5). This detrimental effect
is thought to be mostly attributed to cross-regulation between
Th subsets (6), allowing Th2 cells to polarize immune cells away
from a protective anti-tumor type-1-immunity (7, 8).
The role of CD4+CD8+ double positive (DP) T cells is largely
understudied. Indeed, DP T cells were primarily considered
as a developmental stage in the thymus, before maturation as
either CD4+ or CD8+ (single positive) mature T cells (9). Thus,
in peripheral blood and tissues, most T cells have retained
expression of only one of these co-receptors corresponding
to different functions, with CD8T cells mostly involved in
cytotoxicity toward infected or tumor cells, and CD4T cells
playing helper functions to orchestrate the immune response.
However, mature CD4+CD8+ double positive T cells have
been described in the peripheral blood and tissues in various
settings, including in human cancers (10). The conflicting
literature regarding the role of DP T cells—cytotoxic vs.
immunosuppressive (10)—may indicate that these cells are
heterogeneous and/or show pleiotropic functions that need to be
investigated in each particular disease context. DP T cells have
never been studied in patients with urological cancer. Here, we
quantitatively and phenotypically described DP T cells in blood
from patients with bladder, prostate and kidney cancers. We also
investigated their immunomodulatory functions and found that
DP T cells favor the polarization of naïve CD4+ T cells into a
Th2 functional profile. This previously unrecognized capacity of
DP T cells was observed in healthy donors (HD) and exacerbated
in patients with urologic cancer, who moreover showed elevated
levels of circulating DP T cells.
MATERIALS AND METHODS
Study Population
Fifty four patients with bladder cancer, 29 patients with
kidney cancer, and 31 patients with prostate cancer (mostly male;
Table 1) were recruited at the Lausanne University Hospital.
Peripheral blood was collected in heparin-containing tubes.
Fresh peripheral bloodmononuclear cells (PBMCs) were purified
by density gradient centrifugation (Isopaque-Ficoll) within 2 h
after blood sampling. Cells were cryopreserved in RPMI medium
1640 supplemented with 40% FCS and 10% DMSO. Blood
samples were also collected from 24 healthy volunteers (>50
years old and 80% of male) through the local Swiss blood bank.
Bladder and kidney tumor tissue samples were carefully
collected by pathologist from cystectomy or nephrectomy,
respectively. Tissue samples were then put in a Petri dish
containing RPMI 1640 with 1µg/mL DNAse I (Sigma Aldrich),
cut into small pieces using sterile scissors, transferred into a
sterile strainer and grinded with a syringe plunger in another
Petri dish. The dissociated tissue was rinsed and transferred in
a conical tube through a 40µm filter (Fisher Scientific). After
centrifugation, cells were resuspended in fresh medium, counted
and were subsequently used for flow cytometry analysis.
All patients provided written informed consent prior to their
participation in the study. This study was approved by the ethics
committee of the canton of Vaud, Switzerland (protocol #119/10).
TABLE 1 | Characteristics of urological cancer patients.
Characteristics Bladder Prostate Kidney
N◦ of patients 54 31 29
Age, yr, median (IQR) 70 (62.3–80) 66 (60.5–70.5) 65 (58–69)
SEX, n (%)
Male 42 (77.8) 31 (100) 23 (79.3)
Female 12 (22.2) n.a. 6 (20.7)
TUMOR STATUS, n (%)
pTa 18 (33.3) n.a. n.a.
pT1 12 (22.2) 3 (9.7) 12 (41.4)
pT2 5 (9.3) 17 (54.8) 2 (6.9)
pT3 13 (24.1) 10 (32.3) 14 (48.3)
pT4 1 (1.8) 1 (3.2) 1 (3.4)
CIS alone 5 (9.3) n.a. n.a.
DRAINING LYMPH NODE STATUS, n (%)
Nx 1 (1.8) 2 (6.5) 7 (24.1)
N0 48 (88.9) 28 (90.3) 20 (69)
N1 5 (9.3) 1 (3.2) 0 (0)
>N2 0 0 2 (6.9)
GLEASON
6 n.a. 6 (19.3) n.a.
7 n.a. 22 (71) n.a.
8 n.a. 0 (0) n.a.
9 n.a. 2 (6.5) n.a.
10 n.a. 1 (3.2) n.a.
FURHMAN
I n.a. n.a. 0 (0)
II n.a. n.a. 11 (37.9)
III n.a. n.a. 10 (34.5)
IV n.a. n.a. 6 (20.7)
not determined n.a. n.a. 2 (6.9)
n.a, not applicable.
Flow-Cytometry Analyses
The following mAbs were used at predetermined optimal
concentrations: anti–CCR7-PE, anti–CD3-PeCy7, anti–CD14-
FITC, anti–CD8α-PEAF610 (Invitrogen); anti–CD4-APC/H7
(BD Pharmingen); anti–CD8β-eF660, anti–CD45RA-eF450,
anti–IL4-PeCy7 (eBioscience). FcR Blocking Reagent (Miltenyi
Biotec) was used to block unwanted binding of antibodies and
increase the staining specificity of cell surface antigens. Cells
were stained for surface antigens at 4◦C for 20min, and an
amine reactive dye (Aqua LIVE/DEAD Stain Kit; Thermo Fisher
Scientific) was used for dead cell exclusion according to the
manufacturer’s instructions. A representative example of the
full gating strategy is shown on Supplementary Figure 1A.
When intracellular staining was required, cells were then
fixed and permeabilized using the “Intracellular Fixation and
Permeabilization Buffer Set” (eBioscience) according to the
manufacturer’s recommendations. Cytokine staining was then
performed using anti–INF-È-BV421 (BioLegend) and anti–IL-
4-PeCy7 (eBioscience) for 30min at room temperature. Sample
acquisition was performed on the Gallios Flow Cytometer
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(Beckman Coulter). Analyses were performed using the FlowJo
software (TreeStar).
Generation of DP T-Cell Clones
DP T cells were sorted by FACS sorting (FACSARIA III, BD
Biosciences). Sorted cells were cloned by limiting dilution,
and expanded in RPMI medium 1640 supplemented with
8% human serum, 150 U/mL recombinant human IL-2 (rIL-
2, from Proleukin), 1µg/mL phytohemagglutinin (PHA), and
irradiated allogeneic PBMC (3,000 rad) as feeder cells (feeders
to DP T cells ratio of 2:1). Successfully expanded clones
were checked for purity (only those with >90% DP T cells
were selected) and cryopreserved for subsequent functional
assays. T-cell suppression assay was performed as we previously
described (11, 12).
Bead-Based Multiplex Assay for the
Measurement of Cytokine Secretion by DP
T Cells
DP T-cell clones (30,000 cells/well in a 96 well-plate) were
stimulated during 24 h with plate-bound anti-CD3 antibody
(pre-coated at 2µg/mL overnight at 4◦C) and soluble anti-
CD28 (2µg/mL). Cell-free supernatants were collected and
cytokine concentrations (IFN-γ, TNF-α, IL-4, and IL-5) were
measured using a Luminex assay according to the manufacturer’s
instructions (Thermo Fisher Scientific). Supernatants were also
used for naïve CD4 T-cell conditioning assay as described below.
Th1 vs. Th2 Induction From Naive T Cells
Following Conditioning With DP T-Cell
Supernatants
Naïve CD4+ T cells (CD3+CD4+CD8negCD45RA+CCR7+)
from healthy donors were FACS-sorted (FACSARIA III, BD
Biosciences) and stimulated for 48 h with plate-bound anti-
CD3 and soluble anti-CD28, in the presence of above-described
supernatants (dilution 1:1 with fresh medium) of stimulated
DP T-cell clones from patients or healthy donors. Supernatants
from non-stimulated corresponding DP T-cell clones were used
as a control. Cells were then transferred into a new plate and
fresh supernatant was added. Following a 4 day-incubation, cells
were stimulated for 6 h with PMA/Ionomycin (Cell Stimulation
Cocktail, eBioscience) in the presence of monensin and Brefeldin
A (Protein Transport Inhibitors Cocktail, eBioscience). IFN-
γ and IL-4 expression was measured by intracellular cytokine
staining (as described above). Experiment scheme is depicted
in Figure 4A.
Statistics
Statistical comparisons were evaluated using t-tests or non-
parametric Mann-Whitney (and Wilcoxon, for paired values)
tests, when data passed or failed normality test, respectively.
For multiple comparisons, Kruskal-Wallis test was performed,
followed by Dunn’s post-hoc correction for multiple comparison.
A p < 0.05 was considered statistically significant. All statistical
analyses were performed using GraphPad Prism, version 7
(GraphPad Software).
RESULTS
Identification of DP T Cells in Patients With
Urological Cancers
Using flow-cytometry analysis, we identified CD4+CD8+ double
positive (DP) T cells in peripheral blood mononuclear cells
(PBMCs) from HD and from patients (Table 1) with bladder,
prostate or kidney cancers (Figures 1A,B). According to the CD8
expression level, we defined two subpopulations of DP T cells:
CD4highCD8low and CD4+CD8high (Figures 1A,C). Of note, the
resolution of the labeling did not allow to reliably distinguish
CD4highCD8high from CD4lowCD8high DP T cells (Figure 1A)
within the CD4+CD8high population (13). Nevertheless, the
frequency of total DP T cells (Mean percentage ± SEM of
1.18 ± 0.12 for HD; 2.68 ± 0.19 for bladder; 1.99 ± 0.13 for
prostate; 3.26 ± 0.77 for kidney) was significantly elevated in all
urologic cancers as compared to healthy controls (Figure 1B),
independent of tumor stage or grade (data not shown). This
increase was ascribed to elevated levels of both CD4highCD8low
and CD4+CD8high subsets, except in kidney cancer where the
increase in DP T cells was only attributed to the CD4highCD8low
subset (Figure 1C). These alterations in DP T-cell frequencies
were not owing to a variation in CD4+ or CD8+ single positive
T-cells as their frequency were similar between HD and cancer
patients (Supplementary Figure 1B). Also, the frequency of total
CD3+ T cells was not altered in the blood from cancer patients
(Supplementary Figure 1C).
Memory/Differentiation Phenotype of DP T
Cells
The differentiation profile of DP T cells was assessed by the
analysis of CCR7 and CD45RA expression (14, 15), allowing
the identification of naïve, central memory, effector memory
and terminally differentiated effector memory cells re-expressing
CD45RA (TEMRA) (Figure 2A). In HD, CD4+CD8high and
CD4highCD8low DP T cells showed quite similar differentiation
profiles, which seem intermediate between CD4 and CD8
single-positive T cells (Figure 2B). Strikingly, both DP T-
cell subsets from cancer patients showed a differentiation
profile skewed toward the effector memory phenotype, along
with a shortening of the naïve compartment, as compared
to HD (Figure 2C). Notably, this profile was consistently
and significantly observed in bladder, prostate as wells as
kidney cancers.
To further describe the DP T-cell phenotype, we next
analyzed the phenotype of the CD8 subunits. Indeed, studies
revealed that DP T cells with immunosuppressive function show
a peculiar CD8αα – instead of the conventional CD8αβ –
phenotype (16, 17). In healthy donors, the CD4+CD8high subset
showed a conventional CD8αβ phenotype, while a majority
of CD4highCD8low cells did not express the CD8β subunit
thus showing the peculiar CD8αα phenotype (Figures 2D,E).
Similar profiles were found in patients as in healthy donors
(data not shown). Furthermore, we analyzed the presence of
DP T cells in fresh bladder and kidney tumor tissue from
surgical specimens recovered after cystectomy or nephrectomy,
respectively (Figure 3A). Intratumoral CD4highCD8low and
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FIGURE 1 | Quantification of CD4+CD8+ DP T cells in urological cancer patients. (A) Representative example of CD4highCD8low and CD4+CD8high DP T cells
gated on live CD3+ T cells in PBMC from HD and urological patients. Frequencies of total DP T cells (B) and of the two DP T-cell subpopulations (C) in PBMCs from
HD (n = 24) and urological cancer patients: bladder (n = 54), prostate (n = 31) and kidney cancer (n = 29). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001.
CD4+CD8high DP T cells were detected at variable frequencies
(Figure 3B) and, as found in circulating DP T cells, showed a
CD8αα or CD8αβ phenotype, respectively (Figure 3C).
Th1 and Th2 Cytokine Production by DP T
Cells
As DP T cells have a high capacity to produce cytokines
(18) and are moreover enriched in effector memory cells
in patients with urological cancers, we next interrogated the
cytokine secretion profile of DP T cells from patients compared
to HD. To this purpose, we sorted DP T cells according to
CD8α and β expression (in order to increase the accuracy
of the sorting) from HD and urological cancer patients and
cloned them. CD4+CD8αα and CD4+CD8αβ T cell clones were
then stimulated for 48 h with anti-CD3/CD28 antibodies and
supernatants were harvested to measure levels of antitumor
Th1-type cytokines (IFN-γ, TNF-α), as well as of pro-tumor
Th2-type cytokines (IL-4, IL-5). We expected that the latter
cytokines may be highly produced by DP T cells as a high
frequency of them expressed the Th2 surrogate marker CRTH2
(Chemoattractant Receptor-homologous Molecule Expressed on
T Helper Type 2), compared to the low levels observed in
CD4T cells (Supplementary Figure 2). Indeed, DP T cell clones
from patients were found to secrete levels of IFN-γ and TNF-α
comparable to DP T cells from healthy individuals (Figure 4A).
However, CD8αβ DP T cells from patients were found to secrete
significantly higher amounts of both IL-4 and IL-5, as compared
to HD (Figure 4B). CD8ααDP T cells from patients also secreted
elevated levels of IL-5 (Figure 4B).
Functional Role of DP T Cells Toward
Polarization of Naïve CD4 T Cells
We first interrogated a putative immunosuppressive function of
DP T cells toward CD4 and/or CD8 T-cell proliferation (17),
but found no effect in a CFSE-based suppression assay (data
not shown). Next, as DP T cells secrete cytokines that may favor
Th2 development, we investigated the ability of supernatants
from stimulated DP T cells to polarize naïve CD4T cells into
Th1 vs. Th2 functional profiles (Figure 4C). To this purpose,
we used the above-mentioned supernatants of stimulated and
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FIGURE 2 | Alterations in memory subset distribution among DP T cells from urological cancer patients. (A) Representative example of differentiation phenotype, as
defined by CD45RA and CCR7 labeling of CD4highCD8low and CD4+CD8high DP T cells gated on live CD3+ T cells; naïve: CD45RA+CCR7+; central memory:
CD45RA–CCR7+; effector memory: CD45RA+CCR7+; and terminally differentiated effector memory (TEMRA): CD45RA+CCR7−. (B) Differentiation stage
distribution in DP and conventional single-positive T cells from healthy donors (HD). (C) Comparison between urological cancer patients and HD for each the memory
subsets frequency among DP T cells (mean ± SEM). (D) Representative example of CD8β labeling in CD4highCD8low and CD4+CD8high from PBMC. (E) Proportion
(mean ± SEM) of cells with a CD8αα and CD8αβ phenotype in CD4highCD8low and CD4+CD8high DP T-cell subsets (n = 10 HD). *p ≤ 0.05; **p ≤ 0.01; ***p ≤
0.001; ****p ≤ 0.0001.
non-stimulated DP T cells derived from healthy donors and
patients with urological cancers. As depicted in Figure 4C,
we exposed naïve CD4T cells (CD45RA+CCR7+, sorted from
healthy donors’ blood) to those supernatants for 48 h, along with
T-cell receptor stimulation (using anti-CD3/CD28 antibodies).
Cells were then washed, transferred into new wells and incubated
for 4 days in the presence of renewed DP T-cell supernatants. T-
helper polarization of CD4T cells was analyzed by intracellular
cytokine staining (INF-γ and IL-4) following a 6 h unspecific
re-stimulation (Figure 4D). Supernatants from stimulated DP T
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FIGURE 3 | Frequency of DP T cells in bladder and kidney tumors. (A) Representative example of CD4highCD8low and CD4+CD8high DP T cells gated on live CD3+
T cells in freshly dissociated kidney and bladder tumors. (B) Frequencies of intratumoral CD4highCD8low and CD4+CD8high DP T cells and (C) their CD8α/CD8β
phenotype (mean ± SEM). ****p ≤ 0.0001.
cells strongly increased the frequency of CD4T cells expressing
IL-4, while reducing the frequency of INF-γ-expressing cells
(Figure 4E). As a result, the ratio between INF-γ- and IL-4-
producing cells was dramatically reduced by activated DP T-cell
supernatants (Figure 4F). CD8αα and CD8αβ DP T cells showed
similar ability to shift this ratio (Supplementary Figure 3A).
Interestingly, DP T cells from patients were even more prone
to invert the INF-γ+/IL-4+ CD4 T-cell ratio (Figure 4G), which
could be explained by a stronger ability to restrain the generation
of CD4T cell expressing INF-γ (Supplementary Figure 3B).
These results suggest that DP T cells favor a Th2 over Th1
polarization of CD4T helper cells. Accordingly, compared to
HD, urological cancer patients showed a higher frequency of
circulating Th2 CD4T cells, as assessed by ex vivo CRTH2
expression (Supplementary Figure 3C).
DISCUSSION
Our results indicate that circulating CD4+CD8+ T cells
are increased in patients with urologic cancers, and show
a differentiation profile biased toward an effector memory
phenotype. As expected, DP T cells were found to be high
cytokine producers, but only type-2 cytokines were increased
in patients DP T cells as compared to healthy donors.
Notably, DP T cell were found to favor a Th2 polarization
of CD4T cells in vitro, at the expense of the protective Th1
functional profile known to play a crucial role in anti-tumor
immunity. This newly identified ability of DP T cells was
observed in healthy donors and exacerbated in patients with
urological cancer.
DP T cells were already described in patients with particular
lymphomas (19–21), melanoma (22), breast (23), colorectal
cancer (24), and recently in renal cancer (25). In these contexts,
DP T cells were often analyzed in tumor-infiltrating lymphocytes
(e.g., after amplification and clonal expansion) but were more
rarely quantified in the peripheral blood. Nevertheless, normal
levels of circulating DP T cells were found in patients with
melanoma and Hodgkin’s lymphoma when compared to healthy
donors (19, 22). In contrast, we found a consistent, yet moderate,
increase in the frequency of circulating DP T cells in patients with
all three urological cancers tested.
Mechanisms behind DP T-cell expansion can only be
speculative as origin of circulating DP T cells—i.e., outside the
thymus—remains unclear. Extrathymic DP T cells may originate
from single-positive T cells under particular conditions, as CD4
expression could be acquired following activation of CD8T cells
(26) and conversely, CD4T cells were proposed to co-express
CD8 under continuous antigen stimulation in the presence of
intestinal factors (27). However, analysis of the TCR Vβ usage
by sclerosis- and melanoma-associated T cells suggested that
DP T cells in these contexts may have a clonal origin distinct
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FIGURE 4 | DP T cells favor a Th2 over Th1 polarization of naïve CD4T cells. DP T-cell clones were generated from ex vivo sorted PBMCs of healthy donors (HD) and
urological cancer patients. Clones (3 CD8αα and 4 CD8αβ clones from 3 HD and 6 CD8αα and 4 CD8αβ clones from one patient of each cancer, i.e., bladder,
prostate and kidney) were in vitro stimulated (anti-CD3/anti-CD28) for 48 hours, and concentrations (mean ± SEM) of (A) Th1 (IFN-γ, TNF-α) and (B) Th2 (IL-4, IL-5)
cytokines were measured in supernatants by Luminex. (C) Experimental procedure. Representative examples (D) and percentages (E) of IL-4 and IFN-γ expression
by polarized CD4+ naïve T cells (from 2 HD) upon stimulation in the presence of supernatants from DP T cell clones from HD or patients (described in A,B). (F) Ratio
between IFN-γ- and IL-4-expressing CD4+ T cells upon stimulation is shown and (G) variation (fold change) of this ratio (mean ± SEM) compared when using DP T
cells from patients and HD. *p ≤ 0.05; **p ≤ 0.01; ****p ≤ 0.0001.
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from that of conventional CD4 or CD8 single-positive T cells
(22, 28). In the tumor from a patient with colorectal cancer,
highest tumor-reactivity was observed within DP T cells from
an overrepresented Vβ subset (24). Thus, elevated levels of DP
T cells in cancer contexts may be related to clonal expansion of
cognate DP T cells. This is in accordance with our observation
that DP T cells from urological cancer patients showed elevated
levels of effector memory cells, together with a reduced naive
compartment. Of note, intra-tumor DP T cells were previously
described as showing an effector memory phenotype (22, 23).
How the tumor may directly or indirectly favor DP T-cell
activation/expansion warrants further investigations. Of note, IL-
9 was proposed as a survival and activation factor of DP T cells
in melanoma tumors (29). However, a loss of IL-9-producing
T cells was described in patients with metastatic melanoma
(30). IL-9 was not studied in patients with urological cancers
to date, yet absence of IL-9 mRNA was reported in bladder
tumor cell lines (31). Besides, expansion of extrathymic DP T
cells was reported in≈20% of patients receiving radiotherapy for
Hodgkin’s disease (19). However, radiotherapy in patients with
urological cancers (i.e., pelvic area) is unlikely to be involved in
DP T-cell expansion, as it was suggested to reflect extrathymic
T-cell development as a result of impaired thymic function
following mediastinal irradiation. Altogether, the appearance of
extrathymic DP T cells remains a puzzling question and future
studies such as transcriptomic analyses are required to decipher
their origin.
Beside reactivity toward viral antigens (EBV, Flu, HCV, HIV)
(32, 33), DP T cells seem to show large tumor cross-reactivity
(24), with one clone found to recognize various tumors. DP T
cells were also proposed to recognize self-antigens, as suggested
in melanoma or sclerosis patients (22, 28). In most reports in
cancer contexts, DP T cells were consistently found to showMHC
class I-restricted reactivity to autologous tumor cells, as assessed
by cytokine production, markers of lytic capacity, or bona fide
cytotoxic activity (20–24). As such, they could be considered
as similar to single-positive CD8+ T cells, showing anti-tumor
properties. However, the most notable attribute distinguishing
DP T cells from conventional CD4 and CD8 single-positive T
cells is their higher production of Th2 cytokines. Yet DP T cells
also produce Th1 cytokines, but at similar levels compared to
conventional T cells (22–24). Our data confirmed the general
ability of DP T cells to produce Th2 cytokines and additionally
showed that this production was enhanced in DP T cells derived
from urological cancer patients. It could be speculated that
tumors instruct dendritic cells to favor Th2-cytokine production
by DP T cells, as already known for CD4T cells (34, 35). Indeed,
the tumor microenvironment support polarization of type-2
immune cells, not only in T cells but also in macrophages (i.e.,
M2) (36) and innate lymphoid cells (i.e., ILC2), as we showed in
patients with bladder cancer (11).
Important heterogeneity exists in the function of DP
CD4+CD8+ T cells, which seems to depend on the expression
of the CD8α or β subunit (10). Albeit conflicting results have
been reported about the cytotoxic capacity of CD4+CD8αβ DP
T cells, they seem to have low cytotoxic anti-tumor function
(10, 23, 24, 32), which can be increased in the presence of
IL-9 (29). Besides, CD4+CD8αβ DP T cells may exert helper
functions through the expression of CD40L (37). In contrast,
CD4+CD8αα DP T cells may have an immunosuppressive role.
Indeed, colonic bacteria-induced DP T cells, expressing CCR6
and CXCR6, were shown to produce IL-10 and inhibit T-cell
proliferation via CD39 activity, similarly to Tregs (17, 38).
However, we did not observe any direct suppressive function
when using DP T cells clones, either CD8αα or CD8αβ, isolated
from PBMC of healthy donors or cancer patients. Since CD8αα
DP T cells with regulatory properties have been identified so far
only in colonic mucosa fromHD and patients with inflammatory
bowel disease (17, 38), further investigations are needed to clarify
whether a subset with direct suppressive function may also be
found in cancer patients. Nevertheless, we asked whether and
how DP T cells may influence CD4+ T-cell function. Our data
demonstrated that soluble factors secreted by DP T cells are able
to favor polarization of naïve CD4+ T cells into a Th2 profile,
while restraining Th1 differentiation. Interestingly, this effect was
observed with DP T cells from both healthy donors and patients,
but was even more pronounced when using patients-derived DP
T cells. This could be explained by the higher effector memory
profile associated with higher Th2-type cytokine production
observed in DP T cells from patients, when compared to
healthy donors.
It would be of interest to target DP T cells in order to
improve anti-tumor type-1 immunity. However, direct targeting
of DP T cells may prove to be difficult due to their existence
as a T-cell development stage and to the lack of a specific
marker able to distinguish them from the indispensable single-
positive T cells. Moreover, removal of DP T cells may not be
relevant since, as discussed above, they also show a beneficial
cytotoxic effect toward tumor cells. It may thus be of interest
to specifically target their pro-tumor activities, i.e., the secretion
of Th2 cytokines of which DP T cells seem to be a major
producer as highlighted in this and other studies (22–24). To
this regard, IL-4 blockade in mouse tumor models was shown to
reduce immunosuppressive cells, enhance anti-tumor cytotoxic
T-cell activity and thus delay tumor progression, as well as
synergistically improve immunotherapies (39).
Altogether, DP T cells from patients with urological cancers
are not only increased but particularly prone at favoring a Th2
profile at the expense of Th1 cells, suggesting a deleterious role
with regard to effective antitumor immunity in these patients.
DP T cells and conventional Th2 cells may fuel each other,
promoting a subverted immune contexture allowing urological
tumor escape.
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Supplementary Figure 3 | T helper polarization by DP T cell subsets. (A) Ratio
between IL-4 and IFN-γ expression by polarized CD4+ naïve T cells (from 2 HD)
upon stimulation in the presence of supernatants from CD8αα and CD8αβ DP T
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